These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 20421150)

  • 1. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.
    Riaz A; Gates VL; Atassi B; Lewandowski RJ; Mulcahy MF; Ryu RK; Sato KT; Baker T; Kulik L; Gupta R; Abecassis M; Benson AB; Omary R; Millender L; Kennedy A; Salem R
    Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):163-71. PubMed ID: 20421150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
    Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
    Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
    J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
    Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
    J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
    Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
    J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm.
    Kim HC; Kim YJ; Lee JH; Suh KS; Chung JW
    J Vasc Interv Radiol; 2019 Jan; 30(1):1-8. PubMed ID: 30293734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma.
    Rhee TK; Omary RA; Gates V; Mounajjed T; Larson AC; Barakat O; Sato KT; Mulcahy M; Gordon S; Lewandowski RJ; Salem R
    J Vasc Interv Radiol; 2005 Aug; 16(8):1085-91. PubMed ID: 16105920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.
    Young JY; Rhee TK; Atassi B; Gates VL; Kulik L; Mulcahy MF; Larson AC; Ryu RK; Sato KT; Lewandowski RJ; Omary RA; Salem R
    J Vasc Interv Radiol; 2007 Nov; 18(11):1375-82. PubMed ID: 18003987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
    Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
    J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma.
    Iñarrairaegui M; Martinez-Cuesta A; Rodríguez M; Bilbao JI; Arbizu J; Benito A; Alegre F; D'Avola D; Herrero JI; Quiroga J; Prieto J; Sangro B
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1441-8. PubMed ID: 20056355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations.
    Strigari L; Sciuto R; Rea S; Carpanese L; Pizzi G; Soriani A; Iaccarino G; Benassi M; Ettorre GM; Maini CL
    J Nucl Med; 2010 Sep; 51(9):1377-85. PubMed ID: 20720056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival.
    Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G
    Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.
    Demirelli S; Erkilic M; Oner AO; Budak ES; Gunduz S; Ozgur O; Bozcuk H; Sindel HT; Boz A
    Nucl Med Commun; 2015 Apr; 36(4):340-9. PubMed ID: 25563137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation Segmentectomy and Radiation Lobectomy: A Practical Review of Techniques.
    Malhotra A; Liu DM; Talenfeld AD
    Tech Vasc Interv Radiol; 2019 Jun; 22(2):49-57. PubMed ID: 31079710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Selective internal radiotherapy (SIRT) for hepatocellular carcinoma].
    Antoch G; Mueller SP; Hamami M; Heusner TA; Ertle J; Hilgard P; Forsting M; Bockisch A
    Rofo; 2010 Aug; 182(8):660-70. PubMed ID: 20405369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yttrium-90 Glass-Based Microsphere Radioembolization in the Treatment of Hepatocellular Carcinoma Secondary to the Hepatitis B Virus: Safety, Efficacy, and Survival.
    Biederman DM; Titano JJ; Lee KM; Pierobon ES; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Tabori NE; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2015 Nov; 26(11):1630-8. PubMed ID: 26321014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization.
    Gaba RC; Lewandowski RJ; Kulik LM; Riaz A; Ibrahim SM; Mulcahy MF; Ryu RK; Sato KT; Gates V; Abecassis MM; Omary RA; Baker TB; Salem R
    Ann Surg Oncol; 2009 Jun; 16(6):1587-96. PubMed ID: 19357924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres.
    Dancey JE; Shepherd FA; Paul K; Sniderman KW; Houle S; Gabrys J; Hendler AL; Goin JE
    J Nucl Med; 2000 Oct; 41(10):1673-81. PubMed ID: 11037997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres.
    Lau WY; Ho S; Leung TW; Chan M; Ho R; Johnson PJ; Li AK
    Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):583-92. PubMed ID: 9486608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
    Salem R; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Ibrahim S; Atassi B; Baker T; Gates V; Miller FH; Sato KT; Wang E; Gupta R; Benson AB; Newman SB; Omary RA; Abecassis M; Kulik L
    Gastroenterology; 2010 Jan; 138(1):52-64. PubMed ID: 19766639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.